Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ablynx NV And Merck KGaA's Merck Serono Further Strengthen Their Collaboration On Co-discovery And Co-development Of Nanobodies


Thursday, 26 Sep 2013 01:31am EDT 

Ablynx NV and Merck Serono, the biopharmaceutical division of Merck KGaA, announced that they have further expanded their relationship through a multi-year research alliance that could lead to at least four co-discovery and co-development collaborations. Under the terms of the agreement, Merck Serono will fund a dedicated discovery group at Ablynx. Both partners will jointly select disease targets against which this group will develop Nanobodies, up to in vivo proof-of-principle. The dedicated group will focus on the discovery and development of Nanobodies against a number of targets across multiple disease areas. The collaboration will span all of Merck Serono's core research and development fields, including oncology, immuno-oncology, immunology and neurology. 

Company Quote

8.95
0.04 +0.45%
3:05am EST